This study was supported by the National Key Research and Development Program of China (2023YFC2410200), the National Key Research and Development Project of the Ministry of Science and Technology, China (2019YFC0119900), the International Cooperation and Exchange of the National Natural Science Foundation of China (82020108008), and National Natural Science Foundation of China (82171140, 82301309)
Protection garantie des donnes personnelles via le cryptage SSL
USD 39.95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others References Ying, M
Embracing an active lifestyle, both exercise and beyond
In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to 14.7% compared to 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25]